NCT06607926 2024-09-23Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLCXuanwu Hospital, BeijingPhase NA Not yet recruiting40 enrolled
NCT06598839 2024-09-19Immuno-effect of Tα1 for Stage I NSCLCCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase NA Recruiting40 enrolled